Search results

Evidence-based recommendations on nivolumab (Opdivo) for previously treated advanced renal cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

23 November 2016

Evidence-based recommendations on eribulin (Halaven) for treating locally advanced or metastatic (secondary) breast cancer in adults who have had only 1 course of chemotherapy.

Result type

Technology appraisal guidance

Published

28 March 2018

Evidence-based recommendations on raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women.

Result type

Technology appraisal guidance

Last updated

7 February 2018

This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications.

Result type

NICE guideline

Last updated

25 October 2018

Evidence-based recommendations on topotecan, pegylated liposomal doxorubicin hydrochloride (Caelyx; PLDH), paclitaxel, trabectedin (Yondelis) and gemcitabine. These drugs are for people with ovarian cancer that has come back some time after it was first treated.

Result type

Technology appraisal guidance

Published

27 April 2016

Evidence-based recommendations on cetuximab (Erbitux), bevacizumab (Avastin) and panitumumab (Vectibix) for treating metastatic colorectal cancer in adults.

Result type

Technology appraisal guidance

Published

25 January 2012

Evidence-based recommendations on lenvatinib (Lenvima) and sorafenib (Nexavar) for progressive, locally advanced or metastatic differentiated thyroid cancer in adults who have had radioactive iodine.

Result type

Technology appraisal guidance

Published

8 August 2018

Evidence-based recommendations on raloxifene and teriparatide for preventing osteoporotic fragility fractures in postmenopausal women who have osteoporosis.

Result type

Technology appraisal guidance

Last updated

7 February 2018

Evidence-based recommendations on pegylated liposomal irinotecan (Onivyde) for treating pancreatic cancer in adults.

Result type

Technology appraisal guidance

Published

26 April 2017

Evidence-based recommendations on relugolix (Orgovyx) for hormone-sensitive prostate cancer in adults.

Result type

Technology appraisal guidance

Published

14 August 2024

This guideline sets out an antimicrobial prescribing strategy for preventing recurrent urinary tract infections in children, young people and adults who do not have a catheter. It aims to optimise antibiotic use and reduce antibiotic resistance.

Result type

Antimicrobial prescribing guideline

Last updated

12 December 2024

Evidence-based recommendations on enzalutamide (Xtandi) for treating metastatic hormone-relapsed prostate cancer in adults who have had treatment with docetaxel-containing chemotherapy.

Result type

Technology appraisal guidance

Published

23 July 2014

This guideline covers care and support for adults with cerebral palsy. It aims to improve health and wellbeing, promote access to services and support participation and independent living.

Result type

NICE guideline

Published

15 January 2019

Evidence-based recommendations on erlotinib (Tarceva) and gefitinib (Iressa) for treating non-small-cell lung cancer after chemotherapy in adults.

Result type

Technology appraisal guidance

Published

16 December 2015

Evidence-based recommendations on brigatinib (Alunbrig) for treating anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer in adults who have already had crizotinib.

Result type

Technology appraisal guidance

Published

20 March 2019

Evidence-based recommendations on pembrolizumab (Keytruda) for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy in adults.

Result type

Technology appraisal guidance

Published

28 April 2021

Evidence-based recommendations on durvalumab (Imfinzi) with gemcitabine and cisplatin for treating locally advanced, unresectable, or metastatic biliary tract cancer in adults.

Result type

Technology appraisal guidance

Published

10 January 2024

This guideline covers managing acute and chronic pancreatitis in children, young people and adults. It aims to improve quality of life by ensuring that people have the right treatment and follow-up, and get timely information and support after diagnosis.

Result type

NICE guideline

Last updated

16 December 2020

Evidence-based recommendations on Nivolumab (Opdivo) for previously treated unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

15 June 2021

Evidence-based recommendations on pembrolizumab (Keytruda) for untreated PD-L1-positive metastatic non-small-cell lung cancer in adults.

Result type

Technology appraisal guidance

Published

18 July 2018

Evidence-based recommendations on degarelix (Firmagon) for advanced hormone-dependent prostate cancer in adults with spinal metastases.

Result type

Technology appraisal guidance

Published

24 August 2016

Evidence-based recommendations on necitumumab (Portrazza) for treating locally advanced or metastatic epidermal growth factor receptor (EGFR)-expressing squamous non-small-cell lung cancer in adults who have not had chemotherapy.

Result type

Technology appraisal guidance

Published

28 September 2016

Evidence-based recommendations on bevacizumab (Avastin), with gemcitabine and carboplatin, for treating platinum-sensitive advanced ovarian cancer in adults.

Result type

Technology appraisal guidance

Published

22 May 2013

Evidence-based recommendations on pemetrexed disodium (Alimta) for the maintenance treatment of non-small-cell lung cancer.

Result type

Technology appraisal guidance

Last updated

10 August 2017

Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated unresectable malignant pleural mesothelioma in adults.

Result type

Technology appraisal guidance

Published

17 August 2022

Evidence-based recommendations on gefitinib (Iressa) for untreated locally advanced or metastatic non-small-cell lung cancer in adults.

Result type

Technology appraisal guidance

Published

28 July 2010

Evidence-based recommendations on darolutamide (Nubeqa) with androgen deprivation therapy and docetaxel for hormone-sensitive metastatic prostate cancer in adults.

Result type

Technology appraisal guidance

Published

21 June 2023

Evidence-based recommendations on regorafenib (Stivarga) for treating advanced hepatocellular carcinoma in adults who have had sorafenib.

Result type

Technology appraisal guidance

Published

9 January 2019

Evidence-based recommendations on ceritinib (Zykadia) for untreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer in adults.

Result type

Technology appraisal guidance

Published

24 January 2018

Evidence-based recommendations on selpercatinib (Retsevmo) for treating RET fusion-positive advanced non-small-cell lung cancer (NSCLC) that has not been treated with a RET inhibitor in adults.

Result type

Technology appraisal guidance

Published

19 February 2025

Evidence-based recommendations on radium-223 dichloride (Xofigo) for treating hormone-relapsed prostate cancer with bone metastases in adults.

Result type

Technology appraisal guidance

Published

28 September 2016

Evidence-based recommendations on abemaciclib (Verzenios) with fulvestrant for hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy in adults.

Result type

Technology appraisal guidance

Published

15 September 2021

Evidence-based recommendations on palbociclib (Ibrance) as initial endocrine-based therapy for hormone-receptor positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic (secondary) breast cancer in adults.

Result type

Technology appraisal guidance

Published

20 December 2017

Evidence-based recommendations on cetuximab (Erbitux) for treating locally advanced squamous cell cancer of the head and neck in adults.

Result type

Technology appraisal guidance

Published

25 June 2008

Evidence-based recommendations on everolimus (Afinitor) for treating advanced breast cancer in adults after endocrine therapy.

Result type

Technology appraisal guidance

Published

21 December 2016

Evidence-based recommendations on dacomitinib (Vizimpro) for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in adults.

Result type

Technology appraisal guidance

Published

14 August 2019

Evidence-based recommendations on alectinib (Alecensa) for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer in adults.

Result type

Technology appraisal guidance

Published

8 August 2018

Evidence-based recommendations on topotecan for treating recurrent and stage IVB cervical cancer in adults.

Result type

Technology appraisal guidance

Published

28 October 2009

Evidence-based recommendations on dabrafenib (Tafinlar) plus trametinib (Mekinist) for BRAF V600 mutation-positive advanced non-small-cell lung cancer in adults.

Result type

Technology appraisal guidance

Published

14 June 2023

Evidence-based recommendations on entrectinib (Rozlytrek) for ROS1-positive advanced non-small-cell lung cancer (NSCLC) in adults who have not had ROS1 inhibitors.

Result type

Technology appraisal guidance

Published

12 August 2020

Evidence-based recommendations on everolimus (Afinitor) for advanced renal cell carcinoma after previous treatment.

Result type

Technology appraisal guidance

Published

22 February 2017

Evidence-based recommendations on apixaban (Eliquis) for treating and preventing recurrent deep vein thrombosis or pulmonary embolism in adults.

Result type

Technology appraisal guidance

Published

4 June 2015

Evidence-based recommendations on nivolumab (Opdivo) plus ipilimumab (Yervoy) for untreated unresectable or metastatic colorectal cancer with high microsatellite instability in adults.

Result type

Technology appraisal guidance

Published

28 May 2025

Evidence-based recommendations on cabozantinib (Cabometyx) for untreated advanced renal cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

3 October 2018

Evidence-based recommendations on paclitaxel as albumin-bound nanoparticles (nab-paclitaxel; Abraxane) for untreated metastatic pancreatic cancer in adults.

Result type

Technology appraisal guidance

Published

6 September 2017

Evidence-based recommendations on pembrolizumab (Keytruda) with lenvatinib (Lenvima) for treating advanced or recurrent endometrial cancer in adults.

Result type

Technology appraisal guidance

Published

21 June 2023

Evidence-based recommendations on enzalutamide (Xtandi) for treating high-risk hormone-relapsed non-metastatic prostate cancer in adults.

Result type

Technology appraisal guidance

Published

15 May 2019

Evidence-based recommendations on brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma in adults who have previously had a Bruton’s tyrosine kinase (BTK) inhibitor.

Result type

Technology appraisal guidance

Published

24 February 2021

Evidence-based recommendations on pembrolizumab (Keytruda) for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer in adults.

Result type

Technology appraisal guidance

Published

14 December 2022

This guideline covers diagnosing and managing epilepsy in children, young people and adults in primary and secondary care, and referral to tertiary services. It aims to improve diagnosis and treatment for different seizure types and epilepsy syndromes, and reduce the risks for people with epilepsy.

Result type

NICE guideline

Last updated

30 January 2025